Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.

Goessl C, Katz L, Dougall WC, Kostenuik PJ, Zoog HB, Braun A, Dansey R, Wagman RB.

Ann N Y Acad Sci. 2012 Aug;1263:29-40. doi: 10.1111/j.1749-6632.2012.06674.x. Epub 2012 Jul 25. Review.

PMID:
22831177
2.

Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.

Lipton A, Balakumaran A.

Expert Rev Clin Pharmacol. 2012 Jul;5(4):359-71. doi: 10.1586/ecp.12.35. Review.

PMID:
22943116
3.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.

Clin Ther. 2012 Mar;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. Review.

PMID:
22440513
4.

Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.

Lipton A, Goessl C.

Bone. 2011 Jan;48(1):96-9. doi: 10.1016/j.bone.2010.10.161. Epub 2010 Oct 13. Review.

PMID:
20950721
5.

RANK ligand inhibition with denosumab for the management of osteoporosis.

Lewiecki EM.

Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. Review.

PMID:
16989586
6.

[The clinical merit of anti-RANKL antibody denosumab in prostate cancer].

Akaza H, Tsukamoto T, Suzuki K, Namiki M, Ozono S, Naitodept S.

Gan To Kagaku Ryoho. 2012 Feb;39(2):207-12. Japanese.

PMID:
22333629
7.

[Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].

Yoneda T.

Nihon Rinsho. 2012 Dec;70(12):2165-71. Review. Japanese.

PMID:
23259391
8.

[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].

Varenna M, Gatti D.

Reumatismo. 2010 Jul-Sep;62(3):163-71. Review. Italian.

9.

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.

Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB.

Pharmacotherapy. 2012 Mar;32(3):274-84. doi: 10.1002/j.1875-9114.2011.01092.x. Epub 2012 Feb 13. Review.

PMID:
22392458
10.

Denosumab: benefits of RANK ligand inhibition in cancer patients.

Lipton A, Jacobs I.

Curr Opin Support Palliat Care. 2011 Sep;5(3):258-64. doi: 10.1097/SPC.0b013e328349731c. Review. Erratum in: Curr Opin Support Palliat Care. 2011 Dec;5(4):369.

PMID:
21826000
11.

RANKL inhibition in the treatment of bone metastases.

Lipton A, Jun S.

Curr Opin Support Palliat Care. 2008 Sep;2(3):197-203. doi: 10.1097/SPC.0b013e32830baac2. Review.

PMID:
18685421
12.

Targeting RANKL in breast cancer: bone metastasis and beyond.

Azim H, Azim HA Jr.

Expert Rev Anticancer Ther. 2013 Feb;13(2):195-201. doi: 10.1586/era.12.177. Review.

PMID:
23406560
13.

Denosumab for treatment of breast cancer bone metastases and beyond.

Nangia JR, Ma JD, Nguyen CM, Mendes MA, Trivedi MV.

Expert Opin Biol Ther. 2012 Apr;12(4):491-501. doi: 10.1517/14712598.2012.664634. Epub 2012 Feb 21. Review.

PMID:
22348344
14.

[Anti-RANKL antibody for the management of bone metastasis].

Yoneda T.

Gan To Kagaku Ryoho. 2011 Sep;38(9):1439-45. Japanese.

PMID:
21918338
16.

Denosumab for the treatment of bone metastases in advanced breast cancer.

Casas A, Llombart A, Martín M.

Breast. 2013 Oct;22(5):585-92. doi: 10.1016/j.breast.2013.05.007. Epub 2013 Jun 4. Review.

PMID:
23759273
17.

[Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].

Takahashi S.

Gan To Kagaku Ryoho. 2012 Jan;39(1):89-94. Review. Japanese.

PMID:
22241358
18.

Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.

Perez Ruixo JJ, Doshi S, Sohn W, Chow A.

J Clin Pharmacol. 2015 Mar;55 Suppl 3:S85-92. doi: 10.1002/jcph.388. Review.

PMID:
25707967
19.

An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.

Maldonado-Gonzales E, Pietschmann P.

Wien Med Wochenschr. 2010 Sep;160(17-18):458-63. doi: 10.1007/s10354-010-0812-3. Epub 2010 Aug 16. Review.

PMID:
20714812
20.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.

J Clin Oncol. 2009 Apr 1;27(10):1564-71. doi: 10.1200/JCO.2008.19.2146. Epub 2009 Feb 23.

PMID:
19237632

Supplemental Content

Support Center